MMP2 and atherosclerosis: As the MMP-2/TIMP-2 system contributes to the pathogenesis of atherosclerosis, cardiovascular disease, and the progression of CKD, our findings suggest an underlying pharmacological rationale for the use of β-blockers in clinical practice to reduce inflammation and abnormal vascular remodeling, which predispose the patients with CKD to increased cardiovascular events.